
Joseph Quinn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11409653/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mitochondria are a direct site of AÎ ² accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics, 2006, 15, 1437-1449.	2.9	996
2	Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Human Molecular Genetics, 2004, 13, 1225-1240.	2.9	309
3	Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Disease and Associated Disorders, 2018, 32, 351-358.	1.3	241
4	Centella asiatica: phytochemistry and mechanisms of neuroprotection and cognitive enhancement. Phytochemistry Reviews, 2018, 17, 161-194.	6.5	144
5	Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. Journal of Neuroimmunology, 2003, 137, 32-41.	2.3	117
6	Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Research, 2005, 1037, 209-213.	2.2	100
7	Raman spectroscopy and machine learning for biomedical applications: Alzheimer's disease diagnosis based on the analysis of cerebrospinal fluid. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 248, 119188.	3.9	61
8	Multivariate Statistical Analysis of Surface Enhanced Raman Spectra of Human Serum for Alzheimer's Disease Diagnosis. Applied Sciences (Switzerland), 2019, 9, 3256.	2.5	33
9	Integration of mass spectral fingerprinting analysis with precursor ion (MS1) quantification for the characterisation of botanical extracts: application to extracts of <scp><i>Centella asiatica</i></scp> (L) Urban. Phytochemical Analysis, 2020, 31, 722-738.	2.4	28
10	Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy. Movement Disorders, 2020, 35, 2019-2027.	3.9	25
11	Retention of Alzheimer Disease Research Participants. Alzheimer Disease and Associated Disorders, 2019, 33, 299-306.	1.3	24
12	Tauâ€Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	5.3	19
13	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. Nature Communications, 2022, 13, 1495.	12.8	11
14	Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial. Parkinsonism and Related Disorders, 2021, 86, 10-14.	2.2	8